BUSINESS

• IQVIA, JFCR Cancer Institute Partner to Speed Clinical Trials in Japan
  July 25, 2025

• FRONTEO’s AI Engine Uncovers Novel Pancreatic Cancer Targets as Company Eyes Out-Licensing
  July 24, 2025

• Eisai Launches Beova in Thailand with Rights Obtained from Kyorin
  July 24, 2025

• Towa Launches Task Force to Tackle Nitrosamine Impurities, Share Solutions with Peers
  July 24, 2025

• Alloy Japan Teams with KSAC to Back University Startups’ Global Push
  July 23, 2025

• FDA Panel Rejects Rexulti’s PTSD Bid: Otsuka/Lundbeck
  July 23, 2025

• Santen’s Myopia Drug Ryjunea Now Available in Germany
  July 23, 2025

• Moderna Drops Plan for mRNA API Site in Japan as Vaccine Demand Slumps
  July 22, 2025

• Sanofi to Take Over Japan MA for Beyfortus from AstraZeneca
  July 22, 2025

• Multi-Dose Wegovy Pen Now Available in Japan: Novo
  July 22, 2025

• Enhertu Combo Gets Breakthrough Tag for First-Line HER2 Breast Cancer
  July 22, 2025

• Nippon Chemiphar Signs On to Meiji-Daito Consortium as Talks Accelerate
  July 22, 2025

• Ex-Finance Official Says Treating Obesity Could Lower Japan’s Healthcare Costs
  July 22, 2025

• JRI Urges Reforms in Pricing and Reimbursement to Support Regenerative Medicine Ecosystem
  July 18, 2025

• Astellas Partners with KISED to Support Korean Biotech Startups
  July 18, 2025

• Kowa Picks Up Global Rights to Nicox’s Glaucoma Drug Excluding Asia
  July 18, 2025

• Alnylam’s Amvuttra Could Become First-Line Therapy for ATTR-CM, Says Expert
  July 18, 2025

• Otsuka Taps Autoimmune Diseases as Strategic Pillar for Long-Term Growth
  July 17, 2025

• Nihon Medi-Physics to Deepen Theranostics Ties with Pharma under GE HealthCare
  July 17, 2025

• Balversa Launched in Japan as 1st Genetically Targeted Drug for Bladder Cancer: J&J
  July 17, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 42
• 43
• 44
• 45
• 46
• 47
• 48
• 49
• 50
• …
• Next ›
• 最終 »